Quadrivalent human papillomavirus vaccine: two vaccine doses was also associated with a considerable reduction in condyloma risk


Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility.
Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus ( HPV ) vaccines.
Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine.

A study has examined the association between quadrivalent HPV vaccination and first occurrence of condyloma in relation to vaccine dose in a population-based setting.

An open cohort of all females aged 10 to 24 years living in Sweden ( n = 1 045 165 ) was followed up between 2006 and 2010 for HPV vaccination and first occurrence of condyloma using the Swedish nationwide population-based health data registers.

Incidence rate ratios ( IRRs ) and incidence rate differences ( IRDs ) of condyloma were estimated using Poisson regression with vaccine dose as a time-dependent exposure, adjusting for attained age and parental education, and stratified on age at first vaccination.

A total of 20 383 incident cases of condyloma were identified during follow-up, including 322 cases after receipt of at least 1 dose of the vaccine.

For individuals aged 10 to 16 years at first vaccination, receipt of 3 doses was associated with an IRR of 0.18 for condyloma, whereas receipt of 2 doses was associated with an IRR of 0.29.

One dose was associated with an IRR of 0.31, which corresponds to an IRD of 384 cases per 100 000 person-years, compared with no vaccination.

The corresponding IRDs for 2 doses were 400 cases and for 3 doses, 459 cases.

The number of prevented cases between 3 and 2 doses was 59 per 100 000 person-years.

In conclusion, although maximum reduction in condyloma risk was seen after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was also associated with a considerable reduction in condyloma risk. ( Xagena )

Herweijer E et al, JAMA 2014;311:597-603

XagenaMedicine_2014



Indietro

Altri articoli

UCSD ( University of California San Diego ) researchers have identified the molecular mechanism activated by the presence of tetrahydrocannabinol...


Human papillomavirus ( HPV ) causes nearly all cervical cancers and some cancers of the vagina, vulva, penis, anus, and...


Dacomitinib is an irreversible, pan-epidermal growth factor receptor ( HER ) inhibitor. The goal of a study was to evaluate the...


In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say...


Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ),...


A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a...


HPV initiated ( HPV+ ) squamous cell carcinoma of oropharynx ( SCCOP ) has a unique epidemiology, biology, and genetic...


Although adolescent girls are the main population for prophylactic human papillomavirus ( HPV ) vaccines, adult women who remain at...


A small number of cases of complex regional pain syndrome following vaccination have been reported to the TGA ( Therapeutic...